Adrenal axis suppression unrelated to the dynamics of dosing with beclomethasone monopropionate

British Journal of Clinical Pharmacology

Volumn 63, Issue 3, 2007, Pages 288-291

  Mulrennan, Siobhan A ^a   Hogg, Joseph S ^a   Teoh, Richard C ^a   Morice, Alyn H ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Adrenal axis suppression; Asthma; Beclomethasone

Indexed keywords

17 BECLOMETASONE PROPIONATE; BECLOMETASONE; CREATININE; DEXAMETHASONE; HYDROCORTISONE; PLACEBO; UNCLASSIFIED DRUG;

ADRENAL SUPPRESSION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; BECLOMETHASONE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PITUITARY-ADRENAL SYSTEM; RANDOMIZED CONTROLLED TRIALS;

EID: 33846989341     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02765.x     Document Type: Article

References (15)

1. Kwong FK, Sue MA, Klaustermeyer WB. Corticosteroid complications in respiratory disease. Ann Allergy 1987; 58: 326-30.
2. Urban RCJ, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1988; 31: 102-10.
3. Pederson S, O'Byrne. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52: 1-34.
4. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med 1999; 159: 941-55.
5. Dekhuijzen PN, Honour JW. Inhaled corticosteroids and the hypothalamic-pituitary-adrenal (HPA) axis: do we understand their interaction? Resp Med 2000; 94: 1-5.
6. Rohdewald P, Mollmann HW, Hochhaus G. Affinities of glucocorticoids for glucocorticoid receptors in human lung. Agents Actions 1985; 17: 3-4.
7. Wurthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monproprionate. Biopharm Drug Dispos 1990; 11: 381-94.
8. Anderson P, Ryrfeldt A. Biotransformation of topical glucocorticoids, budesonide and beclomethasone 17, 21-diproprionate in human liver and lung homogenate. J Pharm Pharmacol 1984; 36: 763-5.
9. Daley-Yates PT, Price AC, Sisson JC, Pereira A, Dallow N. Beclomethasone dipropionate. absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51: 400-9.
10. Seale JP, Harrison LI. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Resp Med 1998; 92: 9-15.
11. McIntyre HD, Mitchell CA, Bowler S, Armstrong JG, Wooler JA, Cowley DM. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. Thorax 1995; 50: 1280-4.
12. Nelson HS, Stricker W, Casale TB, Raff H, Fourre JA, Aron DC, Newman KB. A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids. J Clin Pharmacol 2002; 42: 319-26.
13. Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone proprionate in healthy volunteers. Br J Clin Pharmacol 1994; 38: 521-5.
14. Kong WM, Alaghband-Zadeh J, Jones J, Carter G, O'Shea D. The midnight to morning urinary cortisol increment is an accurate, noninvasive method for assessment of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 1999; 84: 3093-8.
15. Lipworth BJ, Wilson AM. Dose response to inhaled corticosteroids: Benefits and risks. Sem Resp Crit Care Med 1998; 19: 625-46.